Dermatology has recently become a point of interest for pharmaceutical innovation. Considering the total number of clinical trials in Phase II, III, and Pre-Registration stages, the already-crowded plaque psoriasis market remains the industry’s top favourite dermatology indication (see Figure 1).

Following closely behind is atopic dermatitis (AD), another hotbed of clinical development marked by the presence of interleukin (IL) inhibitors and oral Janus kinase (JAK) inhibitors in late-stage development. The third indication in line is acne vulgaris, a market that has historically lagged behind in innovation but now boasts of a number of first-in-class therapies in development.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Figure 1: Top dermatology indications based on the number of late-stage clinical trials. Credit: GlobalData.

It is not surprising that the top three indications present as lucrative opportunities for pharma companies, as they have high disease prevalence. GlobalData estimates that the 2018 diagnosed prevalence of plaque psoriasis across the 7MM (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is around 20 million cases, that for atopic dermatitis is around 35 million cases, while for acne vulgaris it is estimated to be around 78 million cases.

However, the reason behind the recent interest of pharmaceutical companies in other, lesser-known dermatological diseases such as alopecia, pruritus, and vitiligo is less obvious. Although they are much less prevalent than the top three indications, as evidenced by the fact that the 2018 diagnosed prevalence of alopecia across the 7MM is around 7 million cases, these markets do present significant unmet needs, and therefore hold substantial opportunities for new drug development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, biologic manufacturers are also exploring niche segments within established diseases in dermatology as an indication expansion strategy, as seen with the recent approval of AbbVie’s Humira (adalimumab) for pustular psoriasis in Japan and the FDA approval of Novartis’ Cosentyx (secukinumab) for scalp psoriasis.

For more insight and data, visit the GlobalData Report Store – Pharmaceutical Technology is part of GlobalData Plc.